Tumors that express CD38, such as PBL and myelomas, are specifically targeted by daratumumab, which exerts its therapeutic effects through antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, complement-mediated lysis, and direct apoptosis [11]. Here, CD38 is linked to plasma cell myeloma.